RG-6146

N/A

Report date: 2024/08/01 20:00:04
NME

Base Information

Drug NameRG-6146
Drug Alias NameJQ-2RG-6146TEN-010RO-6870810
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain and extra terminal domain protein inhibitorsBromodomain-containing protein 4 inhibitorsBromodomain-containing protein 3 inhibitors +[4] 
TargetsBromodomain and extra terminal domain proteinBromodomain-containing protein 3Bromodomain-containing protein 2 +[4] 
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesOvarian Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesDenmark +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesOvarian Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A